<DOC>
	<DOC>NCT01757366</DOC>
	<brief_summary>Safety and Efficacy of Ginsenoside Rg3 in Combination with First-line Chemotherapy in Advanced Gastric Cancer.The purpose of this study is to assess the safety of Ginsenoside Rg3 in advanced gastric cancer, and whether it improves the efficacy of first-line chemotherapy.</brief_summary>
	<brief_title>Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1. Signed informed consent form 2. Performance Status Eastern Cooperative Oncology Group (ECOG) 01; 3. Histologically or cytologically confirmed gastric cancer; 4. At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) 5. Life expectancy of at least 3 months; 1. Received any prior treatment including Ginsenoside Rg3; 2. Active or uncontrolled infection; 3. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; 4. Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>